Skip to main content
Signal8
Launch Terminal

vTv Therapeutics Inc. (VTVT)

vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

vTv Therapeutics Inc. logo

vTv Therapeutics Inc.

NASDAQ:VTVTHealthcare
-4.59%$25.17
AH$25.17+0.00%vs close
Mkt Cap$99.52M
Float1.48M
O/S3.95M
Vol
$ Vol
RVOL
Inst Own40.7%
SI9.7%
Earnings
Dilution
vTv Therapeutics Inc. logoNASDAQ:VTVT$25.17-4.59%
Phase Distribution
14 lead-sponsored trials·1 active·8 completed
Phase 11
Phase 1/22
Phase 28
Phase 33
(1 more as collaborator)
Status Overview
Not yet recruiting1
Active, not recruiting1
Completed8
Stopped4

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Terminated

    Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease

    Azeliragon, Placebo

    Alzheimer's Disease

    Enrollment
    880
    Start
    Apr 2015
    Primary Completion
    Jun 2018
    Completion
    Jun 2018
    NCT02080364
  • Phase 3
    Terminated

    2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)

    Azeliragon 5mg

    Alzheimer's Disease

    Enrollment
    297
    Start
    Dec 2016
    Primary Completion
    Jun 2018
    Completion
    Jun 2018
    NCT02916056
  • Phase 3
    Active, not recruiting

    Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

    Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID

    Diabetes Mellitus, Type 1

    Enrollment
    150
    Start
    Jun 2024
    Primary Completion
    Apr 2027est.
    Completion
    May 2027est.
    NCT06334133
  • Phase 2
    Completed

    Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)

    TTP889

    Venous Thromboembolism, Embolism and Thrombosis +1

    Enrollment
    300
    Start
    Jan 2005
    Primary Completion
    -
    Completion
    Apr 2006
    NCT00119457
  • Phase 2
    Completed

    Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss

    TTP435, Placebo

    Obesity

    Enrollment
    100
    Start
    Feb 2009
    Primary Completion
    Dec 2009
    Completion
    -
    NCT00779519
  • Phase 2
    Terminated

    Left Ventricular Assist Device (LVAD) Specialized Centers of Clinically Orientated Research (SCCOR) Coagulation - Acute Intrinsic Pathway Antagonist (IPA)

    TTP889, Placebo

    Coagulation

    Enrollment
    2
    Start
    Jun 2009
    Primary Completion
    Jun 2010
    Completion
    -
    NCT00909298
  • Phase 2
    Completed

    A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes

    TTP054, Placebo

    Type 2 Diabetes Mellitus

    Enrollment
    186
    Start
    Aug 2012
    Primary Completion
    May 2013
    Completion
    May 2013
    NCT01665352
  • Phase 2
    Completed

    Add Glucokinase Activator to Target A1c

    TTP399 400 mg, TTP399 800 mg

    Diabetes Mellitus, Type 2

    Enrollment
    190
    Start
    Mar 2015
    Primary Completion
    Jul 2016
    Completion
    Sep 2016
    NCT02405260
  • Phase 2
    Completed

    A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes

    TTP273, Placebo

    Type 2 Diabetes Mellitus

    Enrollment
    174
    Start
    Dec 2015
    Primary Completion
    Nov 2016
    Completion
    Jan 2017
    NCT02653599
  • Phase 2
    Terminated

    Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance

    Azeliragon, Placebo

    Alzheimer Disease

    Enrollment
    43
    Start
    Jun 2019
    Primary Completion
    Dec 2020
    Completion
    Jan 2021
    NCT03980730
  • Phase 2
    Not yet recruiting

    Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems

    Cadisegliatin 800 mg QD, Placebo

    Type 1 Diabetes (T1D)

    Enrollment
    40
    Start
    Oct 2026est.
    Primary Completion
    Jun 2027est.
    Completion
    Jun 2027est.
    NCT07616206
  • Phase 1/2
    Completed

    A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes

    GK1-399 (formerly TTP399), GK1-399 (formerly TTP399)

    Type 2 Diabetes Mellitus

    Enrollment
    248
    Start
    Nov 2011
    Primary Completion
    Aug 2012
    Completion
    Sep 2012
    NCT01474083
  • Phase 1/2
    Completed

    Evaluation of TTP399 in Patients With Type 1 Diabetes

    TTP399, TTP399

    Diabetes Mellitus, Type 1

    Enrollment
    115
    Start
    Oct 2017
    Primary Completion
    Dec 2019
    Completion
    Jan 2020
    NCT03335371
  • Phase 1
    Completed

    A Safety Study of TTP4000 in Subjects With Alzheimer's Disease

    TTP4000, Placebo

    Alzheimer's Disease

    Enrollment
    8
    Start
    Oct 2011
    Primary Completion
    Feb 2013
    Completion
    Feb 2013
    NCT01548430
Search ClinicalTrials.gov for “vTv Therapeutics”